
Hemophilia
In a cohort of adults and adolescents marstacimab produced bleed control superior to that from on-demand bypassing agent.
Dr. John Gansner and Dr. Martina H. Slingsby argue this new agent can provide benefit across all bleeding disorders.
Heme Today spoke with Ulrike Reiss, MD, and Andrew Davidoff, MD, of the trial's investigator team.
A preclinical mouse study showed hemostasis restoration, as well as use for active bleeding and internal bleeding prevention.
Fidanacogene elaparvovec gene therapy is a safe and effective treatment for patients with hemophilia B, research shows.
Approval was based on data from phase 3 studies in the ongoing ATLAS clinical development program.
The Clinical Practice Guidance document issued by the EHA, ISTH, EAHAD, and ESO addresses both hemophilia A and B.
A study cohort with severe disease over a median follow-up of 14 months had an annualized bleeding rate of zero.
Advertisement
Expert Interviews on Hematology
Knowledge Hubs
Advertisement